Science Capital: Innovative Healthcare

Detection, Diagnosis and Delivery

balancing therapeutic benefit and cost-effectiveness

Wed 21 Sept 2011 from 5:30-9 pm at the Hotel du Vin Birmingham

Featuring the latest biomedical technologies and innovative thinking within the rapidly evolving healthcare system.   The pressure on the NHS and pharmaceutical industry for change has been intense, and a new model of value-based pricing system is emerging from a consultation with patients, clinicians, the NHS and pharmaceutical industry. This should improve patient access to innovative medicines, and provides tremendous opportunities for development of new diagnostic and therapeutic systems.

Speakers include:

Charlie Craddock directs the Blood and Marrow Transplant Unit at the Queen Elizabeth Hospital, is Professor of Haemato-oncology at the University of Birmingham and founded Cure Leukaemia, and has helped build the case for the region’s investment in biomedical technologies.

Charles de Rohan, CEO of the Binding Site, a Birmingham-based specialist diagnostics company with market-leading products including Freelite® and a growing international reputation for developing innovative products for early detection of disease.  Charles previously led the Genetix Group, a cell imaging and analysis company, and held senior positions at Abbott Laboratories' Diagnostic Division. 

Gordon McKenzie is the Director of Clinical Development at Michelson Diagnostics. He has experience in the field of biomedical optics, and a PhD from the University of Warwick on the interaction of laser light with tissue. Gordon has established a network of senior clinical and health sector contacts, and is an expert at working in the interface between clinicians and technologists. Gordon's roles include managing the clinical trials process showing the efficacy of high resolution Optical Coherence Tomography in disease management.

Paul Moss heads the School of Cancer Sciences at the University of Birmingham, with a research focus on finding ways to engage the body’s immune system in the treatment of leukaemia and the effect of cytomegalovirus on an aging population.

Panel discussion

Join in the debate with leading research and business experts, discuss new developments and present your view.

Present your plan

Obtain feedback on your business idea and explore new partnerships.  Scientists, academics, clinicians and SMEs are invited to present their plans for a free private 45 minute consultation during the afternoon with a panel of legal, business, financial and investment advisors. 

Places are limited. Contact michael@sciencecapital.co.uk for details or to submit your 1 page summary.

Meet the press

Speakers will be interviewed beforehand to share their stories with the public, and members of the press are invited to meet the participants.

Schedule

People will gather at 5:30pm for a canape and drinks reception, to view posters and exhibitor stands, and meet colleagues. 

Talks begin at 6pm, and are followed by lively panel discussions. Dinner will be served from 8pm. 

The evening has been organised to allow ample time to network, a full attendee list is included below to facilitate this.

Sponsorships are available and offer a variety of benefits including exhibitor space, inclusion in the business plan session, and complimentary passes.

For more information:

contact Michael Overduin at

e: michael@sciencecapital.co.uk

m: 07810 444 960 or see

www.sciencecapital.co.uk